Ph.D., Partner, DeciBio Consulting
Dr. Stephane Budel is a partner at DeciBio Consulting with over 18 years of combined experience in life science business consulting, entrepreneurship and academic research. He specializes in helping companies commercialize novel and disruptive technologies in the life science research tools and diagnostic spaces. He has deep genomics expertise, especially as it relates to the impact of next generation sequencing. He has supported clients facing a broad range of challenging business issues, including product specification strategy and commercial due diligence. Dr. Budel earned his Ph.D. from Yale University for his research on the molecular mechanisms of schizophrenia.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Emerging NGS technologies promise to revolutionize applications in the clinic. They are continuously becoming more affordable, yet the requirements for high accuracy, speed, and better reliability remain. This panel will focus on the newest advancements and the technical challenges they encounter to advancing genomics into the clinic, as well as the requirements needed to optimize patient care.